Clinical Trials Logo

Alcohol Withdrawal clinical trials

View clinical trials related to Alcohol Withdrawal.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04997330 Not yet recruiting - Alcohol Withdrawal Clinical Trials

Evaluation of Bilateral HF-rTMS on Abstinence in Alcohol Use Disorder Patients With Executive Dysfunction

STIM-ALC
Start date: September 2021
Phase: N/A
Study type: Interventional

High frequency repetitive transcranial magnetic stimulation (HF-rTMS) over dorsolateral prefrontal cortex (DLPFC) could correct defective executive functions over the hyperactive reward circuit through the meso-fronto-limbic connections. The restored cortical inhibitory control over compulsive alcohol use, could improve abstinence after withdrawal. The goal of this study is to evaluate the efficacy of HF-rTMS over DLPFC in AUD patients with executive dysfunction after withdrawal.

NCT ID: NCT04232800 Not yet recruiting - Clinical trials for Alcohol Use Disorder

Riboflavin for Glutamate Reduction in Alcohol Withdrawal

RGRAW
Start date: December 1, 2021
Phase: Phase 2
Study type: Interventional

This RCT intends to investigate the use of oral Riboflavin (Vitamin B2) for reduction of blood glutamate levels in the setting of acute alcohol withdrawal. Participants will be patients admitted to an inpatient hospital unit diagnosed with acute alcohol withdrawal. In addition to receiving care as usual, they will be randomized to receive either 100mg TID riboflavin or an identically dosed placebo. The primary outcome measure will be blood glutamate levels. Secondary outcomes will include measures of alcohol withdrawal and alcohol craving. The investigators hypothesize that those in the riboflavin group will have lower blood levels of glutamate, as well as decreased symptoms of alcohol withdrawal.

NCT ID: NCT04205682 Not yet recruiting - Alcohol Dependence Clinical Trials

Cannabidiol (CBD) for the Treatment of Alcohol Withdrawal

Start date: January 2020
Phase: Early Phase 1
Study type: Interventional

This study will explore the effectiveness and tolerability of Cannabidiol (CBD) in the treatment of alcohol withdrawal symptoms in an inpatient setting, in a double-blind randomised placebo-controlled trial.